Advertisement
The OR’s Leading Source of Cutting Edge Surgical Technology
Subscribe to Surgical Products All
View Sample

FREE Email Newsletter

Surgical Products Daily

FDA approves Baxter's FLEXBUMIN solution

August 4, 2014 11:36 am | News | Comments

Baxter International announced that the FDA has approved FLEXBUMIN [Albumin (Human)], USP, 5% Solution. FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns and in patients undergoing cardiopulmonary bypass surgery. The FLEXBUMIN 5% solution will be available to U.S. customers later this year. FLEXBUMIN is the first and only preparation of human albumin to be packaged in a flexible plastic container.

Study provides look at future of transcranial ultrasound therapy

August 4, 2014 11:22 am | News | Comments

Research is taking place in transcranial ultrasound therapy, which in the future can potentially be applied to the treatment of brain tumours and targeted drug delivery. The therapy modality has already been successfully applied to the treatment of neuropathic pain disorder and essential tremors. The study focuses on two issues: skull-base heating and formation of standing-waves.

Final patient treated in ALS stem cell procedure

August 4, 2014 11:12 am | News | Comments

Neuralstem, Inc. announced that the final patient was treated in its Phase II trial using spinal cord-derived neural stem cells in the treatment of Lou Gehrig's disease. "The completion of Phase II of this important clinical research program is a major milestone, demonstrating that patients can tolerate the transplantation of high doses of cells and multiple spinal cord injections," said site principal investigator,  Jonathan D. Glass, MD.

Advertisement

Electronic messaging effective reminder for shower regiments

August 4, 2014 10:51 am | News | Comments

The use of electronic reminders is highly effective at getting surgical patients to adhere to a preadmission antiseptic showering regimen known to help reduce risk of surgical site infections (SSIs). Each year about 400,000 SSIs occur and lead to a death rate of nearly 100,000. To reduce the risk of infections, clinicians recommend that patients take antiseptic showers with chlorhexidine gluconate (CHG) 24 to 48 hours before admission.

Once-conjoined twins celebrate 10 years of separation

August 4, 2014 10:24 am | News | Comments

The delicate separation 10 years ago of conjoined twins from the Philippines wasn't perfect, but the boys' mother says their very survival is reason enough to celebrate the anniversary. The boys were separated on Aug. 4, 2004, in an operation that climaxed a then-unusual "staged separation" that took four surgeries over nine months.

2014 ESP Award Submission: Nuvo Vu Surgical Light

July 31, 2014 4:23 pm | Product Releases | Comments

The Nuvo Vu is an LED surgical light with features that include a 160,000 lux, 4,300-degree K color temperature and 95 CRI.

TOPICS:

Group Finds Excellent Clinical Results and Expanded Enrollment in OCCLUDE I Study

July 31, 2014 4:19 pm | News | Comments

ArtVentive Medical Group announced excellent clinical results in conjunction with expanded enrollment in the ArtVentive Endoluminal Occlusion System, OCCLUDE I post-market surveillance study. In conjunction with the study, four female patients were treated for pelvic congestion syndrome and seven male patients were treated for varicoceles using the ArtVentive EOS™ device.

2014 ESP Award Submission: Rapicide Disinfectant

July 31, 2014 4:10 pm | Product Releases | Comments

Crosstex offers their Rapicide OPA/28 High Level Disinfectant, which the company describes as providing a superior way to reprocess heat-sensitive, semi-critical medical devices that are unsuitable for sterilization.

TOPICS:
Advertisement

Kala Pharmaceuticals Initiates Phase 2 Trial

July 31, 2014 3:57 pm | News | Comments

“We are excited about the progress of our lead nanotechnology-based program, LE-MPP, with four active clinical trials,” said Kim Brazzell, Ph.D., Chief Medical Officer of Kala. “With the initiation of our latest trial in RVO and DME, Kala is making significant progress toward demonstrating the unique ability of Kala’s MPP platform to deliver drugs to the back of the eye following topical administration.”

BioTime Expands Clinical Development Of Bladder Cancer Diagnostic

July 31, 2014 3:40 pm | News | Comments

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. OncoCyte’s initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with a reputation for excellence and discovery.

2014 ESP Award Submission: SignatureSuite From Steris

July 31, 2014 3:35 pm | Product Releases | Comments

Steris feels their SignatureSuite, a component of the Harmony iQ OR Integration System, transforms the OR into a serene environment through personalized images, as well as customized music and room settings.

TOPICS:

American CareSource Secures $5 Million Line of Credit

July 31, 2014 3:13 pm | News | Comments

American CareSource Holdings a leading national network of ancillary health care providers and operator of urgent care centers, has closed on a $5 million line of credit with a top-tier U.S. bank, giving the it funding to continue its strategy of acquiring urgent care centers. “The credit facility offers us financial flexibility at a very attractive interest rate," said Dr. Richard W. Turner, Chairman of the Board and CEO.

Women Could Benefit From Tamoxifen Therapy For Breast Cancer

July 31, 2014 2:00 pm | News | Comments

Innovative research has identified a gene signature that has potential to identify which patients will benefit from tamoxifen therapy. Tamoxifen is an endocrine therapy that is one of the most frequently used medications worldwide to treat breast cancer after surgery. However, even among those patients for whom tamoxifen is effective at reducing recurrence risk, many of them experience menopausal-like side effects.

Active O Kicks Off New Clinical Trial Studying Non-Surgical Treatment For Lower Back Pain

July 31, 2014 1:47 pm | News | Comments

A clinical trial being conducted at several high-profile centers in Canada has begun recruiting patients to investigate a new, non-surgical treatment for lower back pain caused by a contained herniated disc. The trial is studying a minimally invasive injection of natural gases designed to dissolve a small amount of disc tissue in order to resolve the disc herniation.

Eighty Percent Of Aortic Stenosis Patients Report Same/Better Health 1 Year After Treatment

July 31, 2014 1:01 pm | News | Comments

A survey of 13,860 patients who had undergone interventions for aortic valve disease has revealed that over 80 percent were in the same or a better state of health one year after the intervention. Aortic stenosis is the most frequent valvular heart disease in the aging Western population, and the prognosis of this disease in symptomatic patients with conservative therapy is poor.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading